Literature DB >> 21271796

Review of treatment response in rheumatoid arthritis: assessment of heterogeneity.

Iris Goetz1, Gebra Cuyún Carter, Melanie Lucero, Victoria Zarotsky, Carlos I Alatorre, Ronald A Cantrell, Rosirene Paczkowski, Kimberly L Sterling.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic, systemic, progressive, inflammatory disorder. The primary goals of treatment in RA are to reduce the signs and symptoms of disease, prevent progression of joint damage and improve patients' physical function. Patients with different sociodemographic characteristics, varying degrees of severity of illness, and comorbidities tend to exhibit differential response to treatment. The purpose of this review was to identify a broad set of factors that are associated with and/or predictive of RA treatment response and determine those that warrant further research. RESEARCH DESIGN AND METHODS: A comprehensive review of the literature from the last 10 years was performed using three key databases (PubMed, EMBASE, and Cochrane). All relevant articles that met the inclusion/exclusion criteria were selected and scored for their levels of evidence using the National Institute of Clinical Excellence (NICE) scoring method. Data on study design, interventions and treatment outcomes were abstracted using a structured abstraction table.
RESULTS: A total of 30 articles were included in the review and data abstraction. Besides gender, baseline clinical variables such as C-reactive protein level, erythrocyte sedimentation rate, measures of disease activity, and Health Assessment Questionnaire scores (based on five patient-centered dimensions) were consistently associated with treatment response over time.
CONCLUSIONS: This comprehensive literature review identified several factors associated with treatment response which might be valuable to include as relevant measures in future studies of RA treatment. Inclusion of these factors, particularly those in the clinical and sociodemographic domains, in the design of future trials will further the understanding that ultimately may help clinicians deliver targeted treatment to community practice RA patients, thus resulting in improved patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271796     DOI: 10.1185/03007995.2010.549805

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Health technology assessment with risk aversion in health.

Authors:  Darius N Lakdawalla; Charles E Phelps
Journal:  J Health Econ       Date:  2020-06-06       Impact factor: 3.883

2.  Heterogeneity of response to biologic treatment: perspective for psoriasis.

Authors:  Emily Edson-Heredia; Kimberly L Sterling; Carlos I Alatorre; Gebra Cuyun Carter; Rosirene Paczkowski; Victoria Zarotsky; Tomoko Maeda-Chubachi
Journal:  J Invest Dermatol       Date:  2013-08-06       Impact factor: 8.551

3.  Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity.

Authors:  Mariem Ben Hamad; Sameh Marzouk; Neila Kaddour; Hatem Masmoudi; Faiza Fakhfakh; Ahmed Rebai; Zouhir Bahloul; Abdellatif Maalej
Journal:  J Clin Lab Anal       Date:  2013-12-27       Impact factor: 2.352

Review 4.  Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.

Authors:  Nitya Nair; Henrik E Mei; Shih-Yu Chen; Matthew Hale; Garry P Nolan; Holden T Maecker; Mark Genovese; C Garrison Fathman; Chan C Whiting
Journal:  Arthritis Res Ther       Date:  2015-05-18       Impact factor: 5.156

Review 5.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

6.  Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.

Authors:  Vivian P Bykerk; Eun Bong Lee; Ronald van Vollenhoven; David C Gruben; Lara Fallon; John C Woolcott; Edward Keystone
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01       Impact factor: 5.178

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.